Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | FORT-2: rogaratinib and atezolizumab in urothelial cancer

Jonathan E. Rosenberg, MD, Memorial Sloan Kettering Cancer Center, New York, NY, explains the findings of the Phase Ib/II FORT-2 (NCT03473756) study, which assesses the safety and efficacy of rogaratinib with atezolizumab in patients with urothelial cancer. Patients were enrolled based on overexpression of FGFR1 or FGFR3 instead of mutational status. In this study, the overall response rate (ORR) of the combination was superior to atezolizumab monotherapy. The safety profile of rogaratinib with atezolizumab was additionally comparable to that of rogaratinib and atezolizumab treatment separately. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.